Vera Therapeutics Inc (VERA) - Net Assets
Based on the latest financial reports, Vera Therapeutics Inc (VERA) has net assets worth $499.70 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($621.74 Million) and total liabilities ($122.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Vera Therapeutics Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $499.70 Million |
| % of Total Assets | 80.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | 768.66% |
| 10-Year Change | N/A |
| Growth Volatility | 195.89 |
Vera Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Vera Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Vera Therapeutics Inc (VERA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Vera Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Vera Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see VERA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $604.52 Million | +4.74% |
| 2024-12-31 | $577.15 Million | +467.59% |
| 2023-12-31 | $101.69 Million | +32.22% |
| 2022-12-31 | $76.91 Million | +10.51% |
| 2021-12-31 | $69.59 Million | +177.89% |
| 2020-12-31 | $-89.35 Million | -144.47% |
| 2019-12-31 | $-36.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vera Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72283100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $71.00K | 0.01% |
| Other Comprehensive Income | $786.00K | 0.13% |
| Other Components | $1.36 Billion | 225.72% |
| Total Equity | $604.52 Million | 100.00% |
Vera Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Vera Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Freshpet Inc
NASDAQ:FRPT
|
$2.51 Billion |
|
TAG IMMOBILIEN ADR 1/2
F:TEG0
|
$2.51 Billion |
|
Beijing Worldia Diamond Tools Co Ltd
SHG:688028
|
$2.52 Billion |
|
Zhuzhou CRRC Times Electric Co. Ltd
F:ZTX
|
$2.52 Billion |
|
Kitron ASA
OL:KIT
|
$2.51 Billion |
|
Hubei Wanrun New Energy Technology Co. Ltd. A
SHG:688275
|
$2.51 Billion |
|
Rogers Corporation
NYSE:ROG
|
$2.51 Billion |
|
Unibel S.A
PA:UNBL
|
$2.51 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vera Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 577,155,000 to 604,521,000, a change of 27,366,000 (4.7%).
- Net loss of 299,615,000 reduced equity.
- New share issuances of 300,500,000 increased equity.
- Other comprehensive income increased equity by 393,000.
- Other factors increased equity by 26,088,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-299.62 Million | -49.56% |
| Share Issuances | $300.50 Million | +49.71% |
| Other Comprehensive Income | $393.00K | +0.07% |
| Other Changes | $26.09 Million | +4.32% |
| Total Change | $- | 4.74% |
Book Value vs Market Value Analysis
This analysis compares Vera Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-10.68 | $35.01 | x |
| 2020-12-31 | $-24.10 | $35.01 | x |
| 2021-12-31 | $5.18 | $35.01 | x |
| 2022-12-31 | $2.89 | $35.01 | x |
| 2023-12-31 | $2.38 | $35.01 | x |
| 2024-12-31 | $10.43 | $35.01 | x |
| 2025-12-31 | $9.41 | $35.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vera Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-49.56%) is below the historical average (-47.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.20 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-44.48 Million |
| 2021 | -46.86% | 0.00% | 0.00x | 1.20x | $-39.57 Million |
| 2022 | -115.80% | 0.00% | 0.00x | 1.71x | $-96.75 Million |
| 2023 | -94.40% | -5155.21% | 0.01x | 1.73x | $-106.16 Million |
| 2024 | -26.36% | 0.00% | 0.00x | 1.14x | $-209.86 Million |
| 2025 | -49.56% | 0.00% | 0.00x | 1.22x | $-360.07 Million |
Industry Comparison
This section compares Vera Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vera Therapeutics Inc (VERA) | $499.70 Million | 0.00% | 0.24x | $2.51 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more